



Application No.: 10/754,922

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

Express Mail No. EL 564 220 201 US First Class Mail ()
Date Mailed January 9, 2004
Serial No. TBA Filed Herewith
Inventor Stavenhagen et al.
For Identification and Engineering of Antibodies with
Variant EC regions and methods of using same

- () Affidavit/Declaration
() Amendment () Response
(X) Application 214 pages
(X) 13 claims 24 drawing sheets
() Assignment () Cover Sheet
() Brief (in triplicate)
(X) Declaration & Power of Attorney
() Executed (X) Unexecuted () Copy
() Declaration of Inventor(s)
() Executed () Unexecuted () Copy
() Design Application
() Disclaimer () Disclaimer Fee
() Disclosure Statement () Form PTO-1449
() w/refs. () w/o refs.
() Drawings, Formal
____ Sheets ____ Figures

- () Fee Address Indication Form
(X) Fee Calculation
() Issue Fee Transmittal
() Notice of Appeal
() Oral Hearing Request/Confirm
() Petition to Extend Time ____ month(s)
() Petition under 37 C.F.R. ____
() Power of Attorney
() by Assignee () Associate () with Revocation
() Request for Correction of Filing Receipt
(X) Sequence Listing w/Computer Readable and Paper Copy
() Small Entity Statement
() Status Letter
() Transmittal Letter

11355 U.S. PTO

10/754922



010904

Other: _____

File No. 11183.004-999 Sender: MEB/JJC/PFB

EXHIBIT A